ESSA Pharma Inc. EPIX
At closeOct 13, 2025, 4:00 PM EDT
52-week range unavailable
- Market cap
- 72.35M
- Shares out
- 44.39M
- Forward P/E
- -3.26
- Volume
- 5.95M
- Open
- 0.2012
- Previous close
- 0.2012
- Day's range
- 0.2012 – 0.2012
- Beta
- 1.84
- Price target
- 9.19 (+4467.8%)
- Earnings date
- Feb 11, 2025
YTD -1.6288 (-89.01%)
Key statistics
- Enterprise value
- -57.59M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -16.10M
- Total cash
- 130.69M
- Total debt
- 342.14K
- Return on equity
- -19.83%
- Short % of float
- 2.59%
- 50-day average
- 2.92
- 200-day average
- 5.40
Analyst view
- Target (low)
- 1.65
- Target (mean)
- 9.19
- Target (high)
- 30.99
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.255.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | -0.18 | — | — | — |
| Dec 17, 2024 | Sep 1, 2024 | -0.19 | -0.14 | +0.05 | +26.32% |
| Aug 5, 2024 | Jun 1, 2024 | -0.26 | -0.16 | +0.10 | +38.46% |
| May 14, 2024 | Mar 1, 2024 | -0.19 | -0.20 | -0.01 | -5.26% |
| Feb 13, 2024 | Dec 1, 2023 | -0.17 | -0.14 | +0.03 | +17.65% |
| Dec 12, 2023 | Sep 1, 2023 | -0.22 | -0.12 | +0.10 | +45.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2024 | Piper Sandler | down | Overweight | Neutral |
| Nov 4, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 1, 2024 | Jones Trading | down | Buy | Hold |
| May 16, 2024 | Oppenheimer | main | Outperform | Outperform |
| Dec 13, 2023 | Oppenheimer | reit | Outperform | Outperform |
| Aug 9, 2023 | Oppenheimer | reit | Outperform | Outperform |
About ESSA Pharma Inc.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- essapharma.com
News
ESSA Announces Completion of Arrangement with XenoTherapeutics 
ESSA Securityholders Approve Acquisition by XenoTherapeutics 
ESSA Pharma Inc. (EPIX) Shareholder/Analyst Call Prepared Remarks Transcript 
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics 
Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Crude Oil Down 2%; US Durable Goods Orders Decline In July
Your note
Sign in to keep a note on EPIX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 19.71% | 8,748,629 | 14.26M | Sep 29, 2024 |
| Bellevue Group AG | 17.75% | 7,879,583 | 12.84M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 9.66% | 4,288,167 | 6.99M | Sep 29, 2024 |
| Morgan Stanley | 9.42% | 4,181,342 | 6.82M | Sep 29, 2024 |
| RTW Investments LP | 7.35% | 3,261,496 | 5.32M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 6.18% | 2,742,936 | 4.47M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avantis U.S. Small Cap Equity ETF | 0.11% | 46,652 | 76.04K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 26,858 | 43.78K | Oct 30, 2024 |
| North Square Inv Tr-North Square Kennedy MicroCap Fund | 0.01% | 5,851 | 9.54K | Sep 29, 2024 |